Results 91 to 100 of about 4,636,278 (309)

Adverse events and in-hospital mortality: an analysis of all deaths in a Norwegian health trust during 2011

BMC Health Services Research, 2017
Background The estimated number of in-hospitals deaths due to adverse events is often different when using data from deceased patients compared with that of a population experiencing adverse events.
Hans Flaatten, Guttorm Brattebø, Bjørn Alme, Kjersti Berge, Jan H. Rosland, Asgaut Viste, Bjørn Bertelsen, Stig Harthug, Sidsel Aardal   +8 more
doaj   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events

Drugs - Real World Outcomes
Background There is a growing interest in products featuring hemp extracts and a demand for more data regarding their safety. To date, there is a paucity of published data on the safety of these products. Methods A retrospective analysis of postmarketing
Colleen M. Kingsbury, Ivori Zvorsky, Kevin Spelman   +2 more
doaj   +1 more source

Bridging the gap: a genetically validated avian chorioallantoic membrane platform for investigation of spontaneous circulating tumor cells

Molecular Oncology, EarlyView.
We established the avian chorioallantoic membrane (CAM) assay as a scalable in vivo model for studying circulating tumor cells (CTCs). Human gastrointestinal tumors spontaneously released genetically validated CTCs that were detected across multiple platforms, demonstrating that the CAM model provides an accessible tool for investigating early cancer ...
Dennis Roth, Rui P. L. Neves, Julia Geheb, Christian Ballmeyer, Nathalie Gaßmann, Kiki C. Andree, Monica Sudarsanam, Christiane Driemel, Celine Örencik, Andrè Franken, Eslam Elmaghraby, Sven H. Loosen, Roderburg Christoph, Sebastian Schoelch, Hans Neubauer, Wolfram T. Knoefel, Nikolas H. Stoecklein, Georg Fluegen   +17 more
wiley   +1 more source

Association of community distress and risk of adverse events on the lung transplant waitlist

JHLT Open
Background: Socioeconomic disparities in lung transplantation outcomes have been well described, but little is known about the impact of community-level disparities amongst waitlisted patients. This study examines the relationship between community-level
Alan M. Jacob, MS, William Brandon, MD, Colin Dunn, MD, Song Zhang, PhD, Ang Gao, MS, Fernando Torres, MD, Adrian C. Lawrence, MD, Irina L. Timofte, MD, Srinivas Bollineni, MD, Manish R. Mohanka, MD, Juan Deleija-Lujano, MD, Adnan Khan, MD, Joseph Crossno, MD, Michael Wait, MD, Matthias Peltz, MD, Christopher A. Heid, MD, Lynn Huffman, MD, Steve Ring, MD, John Murala, MD, Suresh Keshavamurthy, MD, Jaye Weston, MD, Vaidehi Kaza, MD   +21 more
doaj   +1 more source

Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease

FEBS Open Bio, EarlyView.
Repair of neuronal DNA damage in Alzheimer's disease by KCL‐286. (A) Amyloid‐β oligomers and plaques impair neuronal DNA repair pathways, leading to DNA double‐strand breaks and glial activation. (B) KCL‐286 activates RARβ/RXR signalling via retinoic acid response elements (RAREs), associated with increased BRCA1 expression, enhanced DNA repair and ...
Natasha Hill, Hassan Yousef Othman AlMuallim, Elouisa Maddock, Carl Hobbs, Earl Clarke, Maria B. Goncalves, Jonathan P. T. Corcoran   +6 more
wiley   +1 more source

Enhancing Communication about Paediatric Medicines: Lessons from a Qualitative Study of Parents' Experiences of Their Child's Suspected Adverse Drug Reaction [PDF]

, 2012
Background: There is little research on parents' experiences of suspected adverse drug reactions in their children and hence little evidence to guide clinicians when communicating with families about problems associated with medicines.
Smyth, RL, Young, B., Hesselgreaves, H, Munir Pirmohamed (40546), Janine Arnott (128747), Turner, M.A., Anthony J Nunn, Rosalind L. Smyth (80205), Mark A. Turner (114089), Hesselgreaves Hannah, Nunn, Anthony J., Nunn Anthony J., Nunn, Anthony J, Turner, Mark A, Matthew Peak (114087), Hesselgreaves, H., Pirmohamed, Munir, Nunn, AJ, Pirmohamed, M, Peak, M, Munir Pirmohamed, Smyth Rosalind L., Janine Arnott, Arnott Janine, Pirmohamed Munir, Nunn, A.J., Hannah Hesselgreaves (128748), Peak, M., Bridget Young (128749), Hannah Hesselgreaves, Bridget Young, Anthony J. Nunn (114088), Young, Bridget, Matthew Peak, Arnott, J, Turner Mark A., Turner, MA, Young, B, Rosalind L Smyth, Pirmohamed, M., Smyth, Rosalind L., Hesselgreaves, Hannah, Mark A Turner, Smyth, Rosalind L, Arnott, Janine, Young Bridget, Peak Matthew, Arnott, J., Smyth, R.L., Peak, Matthew, Turner, Mark A.   +50 more
core   +1 more source

Efficacy, retention, and safety of baricitinib in real-life: HUR-BIO monocentric experience

Ulusal Romatoloji Dergisi
Objective: This study evaluates the effectiveness, retention rate and safety of baricitinib, including a comparison between baricitinib and a tumour necrosis factor inhibitor (adalimumab) in a real-life cohort of patients with rheumatoid arthritis (RA).
Mustafa Ekici, İrem Yıldız İçli, Ece Ersal Deregözü, Emre Bilgin, Zehra Özsoy, Gizem Ayan, Gül Sandal Uzun, Erdinç Ünaldı, Büşra Fırlatan Yazgan, Gözde Sevgi Kart Bayram, Buğu Bulat, Levent Kılıç, Ali Akdoğan, Şule A. Bilgen, Sedat Kiraz, İhsan Ertenli   +15 more
doaj   +1 more source

Adverse events (AE) costs assessed in Poland based on existing Drug Programs – methodology of the project

Current Issues in Pharmacy and Medical Sciences, 2013
The Drug Programs, Pharmaceutical Care and Pharmaceutical Law section (DPPCPL) within Polish Pharmacoeconomical Society decided to perform a research on the impact of the adverse events treatment costs incurred by National Health Fund (NHF) and by the ...
Monika Szkultecka-Dębek, Mariola Drozd, Nina Wiśniewska, Kazimierz Drozd   +3 more
doaj   +1 more source

From patient advocacy to patient‐driven research: Building active partnerships beginning at the bench to reach the bedside

FEBS Open Bio, EarlyView.
Research is strongest when conducted alongside patients, not just about them. Patient research organizations help integrate patient perspectives into research priorities, study design, and scientific meetings, leading to meaningful patient outcomes and development of relevant therapies.
Jenica H. Kakadia, Rachel Heilmann, Maximiliano Barrientos, Laura MacNeill, Ingrid Vallee, Sarah K. Schultz, Patrick O'Donoghue, Angelica A. Moresco, Victoria M. Siu, Ilka U. Heinemann   +9 more
wiley   +1 more source